BioStock: Respiratorius’ RCD405 shows efficacy in preclinical study

Drug developer Respiratorius continues to gather evidence suggesting that their drug candidate RCD405 may have a role to play in the fight against COPD and severe asthma. Preclinical results from a recent ex vivo study show that the candidate’s effect corresponds to that of existing drugs on the market, which bodes well given its multiple mechanisms of action. BioStock contacted CEO Johan Drott to find out what the latest results mean for the project.

Read the full article at biostock.se:

https://www.biostock.se/en/2021/10/respiratorius-rcd405-shows-efficacy-in-preclinical-study/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se